Slide 1: Third Quarter 2021 Business Update
Third Quarter 2021 Business Update November 16, 2021 PARIS: IPH.PA NASDAQ: IPHA © 2021 Innate Pharma. All rights reserved.
Slide 2: Disclaimer on Forward-Looking Information and Risk Factors
Disclaimer on Forward-Looking Information and Risk Factors This document has been prepared by Innate Pharma S.A. (the “Company”) solely for the purposes of a presentation to investors concerning the Company. This document is not to be reproduced by any person, nor to be distributed. This document co
Slide 3: Speakers on Today's Call
Speakers on Today’s Call Mondher Mahjoubi, MD Joyson Karakunnel, MD, MSc, FACP Chief Executive Officer EVP, Chief Medical Officer Chairman of the Executive Board Yannis Morel, PhD Frédéric Lombard, MBA EVP, Head of Business Development SVP, Chief Financial Officer and Portfolio Strategy (Q&A) (Q&A)
Slide 4: Our Robust Pipeline of Proprietary & Partnered Assets
Our Robust Pipeline of Proprietary & Partnered Assets Program Target Indication Pre-Clinical Phase 1 Phase 2 Phase 3 Status Sézary Syndrome PHASE 2 (FDA FAST TRACK/EMA PRIME DESIGNATION) Preliminary Phase 2 data expected 2022 Early data presented Mycosis Fungoides PHASE 2 Preliminary Phase 2 data ex
Slide 5: Early R&D Focus to Drive Value Through Later Stage Partnerships
Early R&D Focus to Drive Value Through Later Stage Partnerships Drive near-term Advance our Build sustainable value with innovative R&D business through Lacutamab pipeline partnerships • Encouraging preliminary data in • Sanofi advanced Innate’s lead • Strong monalizumab collaboration MF KIR3DL2-exp
Slide 6: Monalizumab Phase 2 Data from COAST trial
MONALIZUMAB Monalizumab Phase 2 Data from COAST trial COAST: An open-label, randomized, phase 2 platform study of durvalumab alone or in combination with novel agents in patients with locally advanced, unresectable, stage III NSCLC Antitumour activity by investigator assessment PFS by investigator a
Slide 7: Monalizumab: Early NSCLC development program underway
MONALIZUMAB Monalizumab: Early NSCLC development program underway Phase 3 program to be initiated, sponsored by AstraZeneca, for patients with unresectable, Stage III NSCLC NSCLC Phase 3 start due in unresectable, Stage III NSCLC STAGE I STAGE II STAGE III STAGE IV Phase 2 NeoCOAST* Phase 2 COAST* S
Slide 8: Monalizumab: Head and Neck cancer
MONALIZUMAB Monalizumab: Head and Neck cancer Innate’s first Phase 3 program, sponsored by AstraZeneca, for patients with IO-pretreated HNSCC HNSCC 2L+ Phase 3 trial underway; 1L Phase 2 data due R/M HNSCC 1L 2L+ Phase 2 Cohort 3 Phase 2 Cohort 2 1L R/M HNSCC Post PDx R/R HNSCC monalizumab + durvalu
Slide 9: ANKET: Innate's Proprietary NK Cell Engager Platform
ANKETTM ANKET™: Innate’s Proprietary NK Cell Engager Platform ANKET™ Harnesses NK cell effector functions against cancer cells, through the most conserved activating receptor on NK cells: NKp46 is a versatile, fit-for- purpose technology that is creating Provides proliferation and activation signals
Slide 10: CD123 targeted IPH6101/SAR443579 Demonstrates Potent Antitumor Activity Against AML
ANKETTM CD123 targeted IPH6101/SAR443579 Demonstrates Potent Antitumor Activity Against AML and Favorable Safety Profile IPH6101/SAR443579 kills AML cells resistant to ADCC IPH6101/SAR443579 induce CD123-expressing cell depletion in NHP with minor cytokine release ADCC-sensitive AML cells ADCC-resis
Slide 11: Optimal Efficacy Requires All Arms in Tetra-specific ANKET
ANKETTM Optimal Efficacy Requires All Arms in Tetra-specific ANKET™ Demonstrate Superiority in Preclinical Model of Tumors Solid tumor models Disseminated tumor models Progressing towards IND enabling studies TAg: Tumor antigen *ADCC-enhanced mAb 11
Slide 12: Developing a New Standard of Care Across KIR3DL2-Expressing T-Cell Lymphomas
LACUTAMAB Developing a New Standard of Care Across KIR3DL2- Expressing T-Cell Lymphomas Cutaneous T-Cell Lymphoma (CTCL) Peripheral T-Cell Lymphoma (PTCL) Phase 2 TELLOMAK Trial Multi-trial Strategy Sezary Syndome Mycosis Fungoides From Relapsed to Frontline PTCL 80-200 patients 2,200-4,400 patients
Slide 13: Key Newsflow Over the Next 12+ Months
Key Newsflow Over the Next 12+ Months Q 4 2 0 2 1 Data Readouts Clinical Progress • Monalizumab Cohort 3 Phase 2 combo HNSCC • Lacutamab r/r PTCL mono Phase 1b starting • Lacutamab r/r PTCL combo Phase 2 starting (IST) • IPH5301 (CD73) Phase 1 starting (IST) • ANKETTM IPH6101/SAR443579 IND-enabling
Slide 14: Early R&D focus to drive value through later stage partnerships
Early R&D focus to drive value through later stage partnerships Drive near-term value Advance our Build sustainable with Lacutamab innovative R&D business through pipeline partnerships • Advancing proprietary NK cell- • Strong monalizumab collaboration • TELLOMAK read-out with MF in targeted platfor
Slide 15: Questions and Answers
Questions and Answers &S innate pharma